Evercore ISI raises Travelers stock price target on buyback potential

Evercore ISI raised its Travelers price target to $321 from $317 and kept an Outperform rating, citing an in-line quarter, an underwriting loss ratio beat, and stronger buyback potential. The firm lifted estimates by 1% and expects $2.5 billion of share repurchases through the remainder of 2026, above the $2 billion consensus. BofA also raised its target to $276 from $257 after Travelers posted Q1 2026 EPS of $7.71 versus $6.97 expected and revenue of $11.92 billion versus $10.75 billion.

Analysis

TRV looks like a classic “good enough but not great” compounding story where the market is likely underappreciating buyback torque. If management truly steps up repurchases into a softer pricing backdrop, EPS can outgrow underlying premium growth for several quarters, which matters more at 11x earnings than another 1-2 points of top-line growth. That creates a valuation support floor: a low-multiple insurer with visible capital return capacity tends to re-rate quickly once buyback cadence becomes explicit.

The second-order effect is competitive rather than macro: a slower pricing environment should widen the gap between carriers with superior capital generation and those still chasing growth. TRV can defend share without sacrificing returns because underwriting discipline and repurchases offset weaker rate momentum, while higher-cost peers may feel pressure to either slow growth or accept weaker margins. That makes this less a sector-wide beta trade and more a relative quality screen within P&C.

The market seems to be discounting the soft market already, but the real risk is that buyback expectations get crowded in before they materialize. If personal lines weakness persists and reserve development normalizes, the stock can drift despite the cheap multiple, especially if broader financials rerate down with rates. The key reversal catalyst would be any evidence that renewal price deceleration is stabilizing faster than feared or that excess capital is being returned above the current consensus path over the next 1-2 quarters.

Key Decisions for Investors

• Add TRV on pullbacks over the next 2-4 weeks; target a 6-10% upside rerating toward the revised fair value if buyback execution confirms, with downside limited by low-teens earnings multiple support.
• Pair trade: long TRV / short a more growth-dependent P&C insurer with weaker capital return visibility over the next 1-2 quarters; thesis is capital-return compounding outperforming premium-growth chasing in a soft market.
• Use TRV Jan-2027 call spreads to express the buyback surprise case; attractive if capital returns step up, with defined risk versus owning the equity into a potentially choppy underwriting cycle.
• If TRV rallies >8% on the next capital-return update without an upward earnings revision, trim 25-50%; the market may front-run the buyback story before the actual EPS impact lands.